Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Pfizer acquires Trillium Therapeutics for $2.22bn
Pfizer has completed the acquisition of all outstanding shares of clinical-stage immuno-oncology firm Trillium Therapeutics in a deal worth about $2.22bn, or $18.50 per share, in cash.
Research & Development
-
18 Nov 2021
-
17 Nov 2021
Acelyrin raises $250m through Series B round
Acelyrin has raised $250m through the series B financing round to license and acquire other programmes with focus on immunology.
-
11 Nov 2021
AbbVie, University of Chicago extend oncology research collaboration
AbbVie has extended a collaboration agreement with the University of Chicago until 2025 to support preclinical research in oncology.
-
10 Nov 2021
Regenxbio, AbbVie close license and collaboration deal to develop RGX-314
Biotechnology firm Regenxbio and AbbVie have closed the previously announced license and collaboration deal for the development and commercialisation of the former’s gene therapy, RGX-314.
-
03 Nov 2021
Dunad, Novartis partner to develop oral protein degrader therapies
Dunad Therapeutics and Novartis have signed a strategic collaboration and license agreement to develop next generation targeted protein degrader therapies.
-
02 Nov 2021
Synthekine, Merck partner to develop new cytokine-based therapies
Synthekine and Merck have signed a global research collaboration and license agreement to develop novel cytokine-based therapeutics.
-
29 Oct 2021
Gilead, Merck to study combination therapy for breast cancer
Gilead Sciences and Merck have signed an agreement to assess the efficacy of Trodelvy (sacituzumab govitecan-hziy) in combination with Keytruda (pembrolizumab) to treat patients with metastatic triple-negative breast cancer (TNBC).
-
28 Oct 2021
Immunai raises funding to expand drug actuary platform
Biotech company Immunai has raised $215m in Series B funding round to accelerate the development of its immune-first drug actuary platform.
-
28 Oct 2021
Takeda to buy GammaDelta to accelerate allogeneic cell therapies development
Takeda Pharmaceutical has exercised its option to acquire GammaDelta Therapeutics to accelerate development of allogeneic γδT cell therapies to address solid tumours.
-
27 Oct 2021
Teva, Modag to develop drug candidates for neurodegenerative disease
Teva Pharmaceutical has partnered with Modag for the development and licensing of the latter's drug candidates, anle138b and sery433, for neurodegenerative disease.